Back to Peptides

CJC-1295

Growth Factors & Muscle Building

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), designed with a longer half-life to support prolonged GH secretion in research settings. It is studied for its pharmacokinetic improvements over natural GHRH, especially when combined with GHRP peptides. The DAC modification allows for extended half-life and reduced injection frequency while significantly elevating IGF-1 levels.

Reconstitute
3 mL BAC + 2mg vial
7 mcg/unit
Daily Range
50–150 mcg Subcutaneous (SQ)
2-3 times daily (typically before meals or at bedtime)
Standard Dose
100 mcg
Cycle
4–8 weeks
then reassess
CJC-1295GHRH analoggrowth hormoneIGF-1muscle growthfat reduction

Dosing & Reconstitution Guide

In human research settings, CJC-1295 with DAC has been administered at 1–2 mg per week. These doses were used in tightly controlled environments. It is not approved for general use.

Standard / Gradual Approach

2mg Vialstandard
PhaseDoseVolume
Week 1500mcg75 units
Week 2500mcg75 units
Week 31000mcg150 units
Week 41000mcg150 units

Protocol Summary

Subcutaneous (SQ): 2-3 times daily (typically before meals or at bedtime) · Dose range 50–150 mcg with gradual titration
Cycle Length: 4–8 weeks typical; reassess before extending

Frequency & Cycling

SubQ Injection

CJC-1295 DAC: 500 mcg 1–2x per week. CJC-1295 no DAC: 50-150 mcg before bed or post-workout for 5 days on 2 days off. Recommended cycle: 8–12 weeks with equal time off.

🧪 Quick Start

Vial Size
2 mg
BAC Water
3 mL
Concentration
700 mcg/unit

Potential Benefits & Use Cases

CJC-1295 is a research compound not approved by the FDA for any medical purpose. All studies referenced were conducted in animals or clinical research volunteers under supervision
Produces sustained 2–10 fold GH elevation and 1.5–3 fold IGF-1 elevation in a dose-dependent manner (human trial)
May promote increased lean body mass, reduced fat mass, and improved body composition (preclinical)
Enhances protein synthesis and recovery potential through anabolic signaling (preclinical)
May support deeper sleep through GHRH's documented role in sleep architecture (preclinical)
Clinical data Strong preclinical Limited data

Mechanism of Action

→GHRH receptor agonist
→Stimulates growth hormone secretion
→Extends pulsatile GH release via DAC binding to albumin

Stacking Synergies

+
Ipamorelin
Amplifies GH release when stacked with Ipamorelin
+
Elamipretide
GHRP-6 or GHRP-2 may potentiate pituitary response synergistically

Lifestyle & Optimization

diet

Adequate protein (0.8–1g per pound body weight) and complex carbohydrates.

sleep

Consistent sleep schedule with 7–9 hours nightly — GHRH is most effective during sleep.

timing

Inject 2–3x daily, ideally before bed and post-workout.

exercise

Regular resistance training 4–5 times per week.

Peptide Research & Preclinical Studies

Evidence-Based Research Findings

Study TitleType
J Clin Endocrinol Metab (2006) — Teichman SL et al. Prolonged GH by CJC-1295Reference
J Clin Endocrinol Metab (2006) — Ionescu M et al. Pulsatile GH secretionReference
Am J Physiol (2006) — Alba M et al. Once-daily CJC-1295Reference
StatPearls — Physiology, Growth HormoneReference
Postgrad Med J (2006) — Ayuk J, Sheppard MCReference

Side Effects & Safety

Common Side Effects

• Transient flushing, headache, or water retention during initial titration

🧮 Dose Calculator

Concentration
6.7
mcg/unit
Draw Volume
75
units (0.750 mL)
For a 500 mcg dose, draw 75 units on a U-100 insulin syringe
🧬

Bioavailability & Absorption

SubQ Injection
High bioavailability due to slow-release design; once or twice weekly dosing effective
Oral Administration
Unavailable due to first-pass degradation
Half-Life
6–8 days with DAC (versus 30 minutes without)
Degradation
Slow enzymatic breakdown via albumin-binding system
Tissue Specificity
Targets pituitary somatotrophs to stimulate pulsatile GH secretion
⚗️

Peptide Details

Molecular Weight
3647.2
Formula
C165H269N47O46
Sequence
Modified GHRH sequence with DAC
⚖️

Legal Status & Regulatory

RegionStatus
EUNot Approved
FDANot Approved
CanadaNot Approved
AustraliaNot Approved

Storage Instructions

Lyophilized (Powder)
Store lyophilized powder at room temperature (18-25°C) before reconstitution, then refrigerate at 2-8°C
Reconstituted (Mixed)
After reconstitution, . Reconstituted solution is stable for 30 days when properly stored.